BioCardia Inc. - Prakiraan wutah bathi kanggo taun ngarep BCDA

The stability of BioCardia, Inc. (BCDA) is supported by a strong team of cardiobiologists and a chart where the current valuation of the company's EPS growth for next year demonstrates a positive trend. The 18.20 level captures fresh values. The operational base relies on the creation of a myocardial drug delivery system, which ties medical centers to the brand, while the massive unmet demand for cell therapy guarantees large-scale sales upon completion of testing.

BCDA: Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep BioCardia Inc. 04.07.2022 - 10.11.2026

biocardia.com - rincian analitis lan metrik utama (BCDA)

- rega lan prakiraan konsensus rega:

Bagan rega BioCardia, Inc|BCDA - Konsensus nilai wajar

- rincian nilai pasar emiten:

Kapitalisasi pasar BioCardia|BCDA - Nilai Bisnis

- indikator kapitalisasi buku:

Nilai Buku saben Saham BioCardia|BCDA - Pambiji Buku Bisnis|Rasio Kapitalisasi Pasar marang Nilai Buku biocardia.com|BCDA - Total Aset Perusahaan

- statistik kawajiban utang lan likuiditas:

Rasio Total Utang marang Ekuitas BioCardia, Inc.|BCDA - Koefisien utang jangka dawa marang modal|Utang jangka cendhak marang modal BioCardia|BCDA - Gunggung kewajiban utang perusahaan|Rasio utang marang kapitalisasi buku BioCardia|BCDA - Tanggungan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan BioCardia|Indikator likuiditas cepet biocardia.com

- informasi bathi lan kelipatan valuasi:

Analisis wiwitan perusahaan:BCDA, BioCardia, Inc

This indicator reflects the expected earnings per share (EPS) trend, allowing for an assessment of capitalization potential via analyst consensus forecasts for the upcoming period. By analyzing the consensus EPS growth for next year, investors can gauge the scaling potential of BioCardia, Inc. (BCDA), which is currently limited by logistical disruptions in raw material supplies from Asia and the complexities of international patent regulation.

Perusahaan pesaing